Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joohyuk Sohn

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2024
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer StudyMiguel Martín, Elgene Lim, Mariana Chavez-MacGregor, et al.
British Journal of Cancer|November 7, 2019
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)Sung Hoon Sim, In Hae Park, Kyung Hae Jung, et al.
Communications Biology|April 10, 2021
Genomic landscape of extraordinary responses in metastatic breast cancerSun Min Lim, Eunyoung Kim, Kyung Hae Jung, et al.
Nature Medicine|June 4, 2025
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trialElizabeth A Mittendorf, Zoe June Assaf, Nadia Harbeck, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2024
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancerChanghee Park, Koung Jin Suh, Se Hyun Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2018
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)Ji-Yeon Kim, Seock-Ah Im, Kyung Hae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast CancerVeronique Dieras, Giuseppe Curigliano, Miguel Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2026
Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trialKomal Jhaveri, Hope S Rugo, Javier Cortés, et al.
Journal of the National Cancer Institute|May 11, 2023
Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancerMin Hwan Kim, Gun Min Kim, Jin Mo Ahn, et al.
The New England Journal of Medicine|May 31, 2023
Capivasertib in Hormone Receptor-Positive Advanced Breast CancerNicholas C Turner, Mafalda Oliveira, Sacha J Howell, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2024
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer StudyMiguel Martín, Elgene Lim, Mariana Chavez-MacGregor, et al.
British Journal of Cancer|November 7, 2019
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)Sung Hoon Sim, In Hae Park, Kyung Hae Jung, et al.
Communications Biology|April 10, 2021
Genomic landscape of extraordinary responses in metastatic breast cancerSun Min Lim, Eunyoung Kim, Kyung Hae Jung, et al.
Nature Medicine|June 4, 2025
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trialElizabeth A Mittendorf, Zoe June Assaf, Nadia Harbeck, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2024
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancerChanghee Park, Koung Jin Suh, Se Hyun Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2018
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)Ji-Yeon Kim, Seock-Ah Im, Kyung Hae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast CancerVeronique Dieras, Giuseppe Curigliano, Miguel Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2026
Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trialKomal Jhaveri, Hope S Rugo, Javier Cortés, et al.
Journal of the National Cancer Institute|May 11, 2023
Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancerMin Hwan Kim, Gun Min Kim, Jin Mo Ahn, et al.
The New England Journal of Medicine|May 31, 2023
Capivasertib in Hormone Receptor-Positive Advanced Breast CancerNicholas C Turner, Mafalda Oliveira, Sacha J Howell, et al.
Pageof 13